Skip to main content

CORRECTION article

Front. Neurol., 18 April 2017
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Volume 8 - 2017 | https://doi.org/10.3389/fneur.2017.00145

Corrigendum: Twenty-Year Clinical Progression of Dysferlinopathy in Patients from Dagestan

This article is a correction to:

  1. Twenty-Year Clinical Progression of Dysferlinopathy in Patients from Dagestan

    1. Read original article
Zoya R. UmakhanovaZoya R. Umakhanova1Sergey N. BardakovSergey N. Bardakov2Mikhail O. MavlikeevMikhail O. Mavlikeev3Olga N. ChernovaOlga N. Chernova3Raisat M. MagomedovaRaisat M. Magomedova1Patimat G. AkhmedovaPatimat G. Akhmedova1Ivan A. Yakovlev,*Ivan A. Yakovlev3,4*Gimat D. DalgatovGimat D. Dalgatov4Valerii P. FedotovValerii P. Fedotov5Artur A. IsaevArtur A. Isaev4Roman V. Deev,,\r\nRoman V. Deev3,4,6
  • 1Dagestan State Medical Academy, Makhachkala, Russian Federation
  • 2S.M. Kirov Military Medical Academy, Saint Petersburg, Russian Federation
  • 3Kazan Federal University, Kazan, Russian Federation
  • 4Human Stem Cells Institute, Moscow, Russian Federation
  • 5Voronezh Regional Clinical Hospital No.1, Voronezh, Russian Federation
  • 6Ryazan State Medical University, Ryazan, Russian Federation

A corrigendum on

Twenty-Year Clinical Progression of Dysferlinopathy in Patients from Dagestan
by Umakhanova ZR, Bardakov SN, Mavlikeev MO, Chernova ON, Magomedova RM, Akhmedova PG, et al. Front Neurol (2017) 8:77. doi: 10.3389/fneur.2017.00077

The “Funding” section should be:

This work was funded by Human Stem Cells Institute PJSC and Roman V. Deev. Theoretical part of this work was supported by Russian Scientific Foundation grant (14-15-00916). Ivan A. Yakovlev and Mikhail O. Mavlikeev were supported by the Russian Government Program of Competitive Growth of Kazan Federal University.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: dysferlinopathy, LGMD2B, Miyoshi myopathy, dysferlin, muscular dystrophy

Citation: Umakhanova ZR, Bardakov SN, Mavlikeev MO, Chernova ON, Magomedova RM, Akhmedova PG, Yakovlev IA, Dalgatov GD, Fedotov VP, Isaev AA and Deev RV (2017) Corrigendum: Twenty-Year Clinical Progression of Dysferlinopathy in Patients from Dagestan. Front. Neurol. 8:145. doi: 10.3389/fneur.2017.00145

Received: 21 March 2017; Accepted: 31 March 2017;
Published: 18 April 2017

Edited and Reviewed by: Ghazala Hayat, Saint Louis University, USA

Copyright: © 2017 Umakhanova, Bardakov, Mavlikeev, Chernova, Magomedova, Akhmedova, Yakovlev, Dalgatov, Fedotov, Isaev and Deev. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ivan A. Yakovlev, ivan@ivan-ya.ru

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.